Nasdaq 100 Stocks SEC Filings — October 13, 2026

Director Stat Lauren Elaina Friedman sold 5,026 Class A shares at $199.00 (~$1M) and holds 46,402 shares afterward, executed under a Rule 10b5-1 plan, which reduces the signal weight of the sale

Ryan D. Taylor sold 18,000 shares at $201.15 (~$3.62M) leaving 274,667 shares, pre-planned under Rule 10b5-1; combined with the Friedman sale, roughly $4.6M of insider selling in one filing batch

Director Jarrod M. Patten sold 950 shares at $150.54 (~$143K) and 450 at $152.00 (~$68.4K) while exercising 1,400 options at $18.24 (~$25.5K); holds 28,406 shares, so the sale is a small fraction of holdings but net-negative for the batch

EVP & Chief Legal Officer Gary Loeb exercised/converted 2,612 shares and RSUs and had 1,296 shares withheld for taxes at $423.96 (~$549K), leaving 6,636 shares; withholding reflects vesting settlement, not open-market selling

SVP Chief Human Resources Officer Patricia L. Wadors exercised/converted 2,140 shares/RSUs with 1,062 withheld for taxes (~$450K), leaving 1,078 shares; a small residual holding after settlement is worth monitoring for further sales

Chair & CEO Vincent Roche gifted 13,305 shares, a charitable/estate transfer rather than a market sale, which is a neutral-to-mildly positive signal on personal conviction retention

EVP Global Sales Oliver Tuszik had 2,259.591 shares withheld for taxes at $118.39 (~$268K) and still holds 230,690.08 shares, a substantial stake consistent with long-term alignment

Director Girish D. Rishi was awarded 419 shares, a standard board compensation grant that adds to his holding without any open-market purchase or sale

EVP Worldwide Field Ops Nicholas P. Parker was awarded 160,418 shares via an amended Form 4 (4/A); the amendment itself is a disclosure-hygiene item, while the sizeable grant indicates strong retention incentives

October 13, 2026 8-K furnishes Regulation FD material and a press release (Exhibit 99.1, dated October 12, 2026) on capital markets and capital management updates; the substance is in the exhibit and must be reviewed before drawing a directional conclusion

Two Rule 10b5-1 sales totaling roughly $4.6M in one batch (Friedman ~$1M, Taylor ~$3.62M); although pre-planned, clustered sales can still be read as reduced insider conviction at elevated prices near $200

DEFA14A supplemental proxy filing dated October 13, 2026 references an August 3, 2026 proxy, but the excerpt contains no proposal details, so the nature of any shareholder vote or contested item is unknown and warrants full document review

The 8-K body contains no quantitative results, pushing all capital-markets detail into Exhibit 99.1 and a website dashboard; investors relying on the filing text alone cannot assess the update

Director Patten's sales came at $150.54 and $152.00 while the same filer exercised options struck at $18.24, indicating realization of gains; a repeated pattern across filings would be a concern

Post-transaction holdings for Gary Loeb (6,636 shares) and Patricia Wadors (1,078 shares) are small relative to annual vesting, so future tax withholding may drive further net share reductions

Chair & CEO Vincent Roche's 13,305-share gift is a non-market disposition at materiality 7/10; while likely estate or charitable planning, it reduces direct insider ownership and should be checked against Form 4 footnotes for the recipient

Period-over-period, forward-looking guidance, and financial ratio fields are absent from every excerpt in this batch, so trend-based risk assessment (margins, leverage, guidance cuts) cannot be performed and should not be inferred from this digest

EVP Tuszik's 230,690 share holding after tax withholding signals durable long-term alignment; the withholding itself is compensation-driven, supporting a constructive view with no open-market selling in this batch

The 160,418-share award to EVP Parker (4/A) provides a meaningful retention incentive for a senior field-operations leader in an AI-driven demand cycle; investors can track vesting schedules in the next proxy

The October 12, 2026 press release (Exhibit 99.1) announcing capital markets and capital management updates is a near-term catalyst; retrieving Exhibit 99.1 and the strategy.com dashboard for securities prices, bitcoin holdings, and KPIs is the immediate action item

The CEO's gift rather than market sale means no open-market supply from the chair; combined with the neutral-to-positive read, the absence of selling pressure from top management is a supportive technical point

Two executives' RSU and option settlements in the same filing window suggest a regular annual cycle rather than an ad hoc event, making the timing predictable for investors modeling insider supply

Intuitive Surgical (2 officers, ~$999K combined withholding), Cisco (1 officer, ~$268K), and NVIDIA's award reflect a common equity-compensation settlement cycle across large-cap tech and medtech; withholding is mechanical and should not be read as directional selling

Both Palantir sales (~$4.6M combined) were executed under 10b5-1 plans, consistent with pre-scheduled diversification rather than discretionary bearish signaling; this distinction matters for interpreting insider sales across the group

Cisco's director award (419 shares) and Strategy Inc's director option exercise and sales illustrate board-level equity participation, with director sales ($211K across Strategy Inc sales) small relative to the disclosed holdings

The NVIDIA 4/A amendment and the duplicated Strategy Inc DEFA14A filings point to routine filing-hygiene activity; separately, Regulation FD and exhibit-based disclosure (Strategy Inc 8-K) shifts substance into referenced exhibits, a pattern that requires full-document review rather than summary reading

Retrieve the October 12, 2026 capital markets press release and the full DEFA14A tied to the August 3, 2026 proxy; key to assessing any vote or capital action [date: 2026-10-12 release; 2026-08-03 referenced proxy]

Monitor whether Friedman and Taylor sales continue under their plans and whether additional director or officer sales cluster near $200 [ongoing, next Form 4 window]

Track Loeb (6,636 shares) and Wadors (1,078 shares) for further disposals as RSUs vest and withholding recurs [next vesting cycle]

Review the Form 4 footnote for the 13,305-share gift to confirm recipient type (charitable, family trust) and any follow-on transfers [ongoing]

Track vesting schedule for the 160,418-share award and any subsequent Form 4 activity from the EVP [next proxy and Form 4 filings]

Monitor the 230,690-share position for any open-market change following the recent withholding event [ongoing Form 4 monitoring]